Shares of Apollo Hospitals Ltd. gained over 5% to hit a fresh all-time high on Friday, November 20, after global investment banking firm Macquaire upgraded its rating and raised its target price, indicating an upside of 20.2% from its previous closing price.
Macquarie has double-upgraded Apollo Hospitals to “outperform” from “underperform” and has raised its target price to ₹10,500 from ₹6,230 earlier.
Apollo Hospitals shares extended their gains for the second month, rising 8% in November, so far, after gaining 3.5% in October. This is also its biggest monthly gain since February this year, when it had risen 12.4%. The stock has risen for seven out of the 11 months in 2026, so far.
Macquarie believes the consensus earnings have bottomed out and valuations have cooled off. The initial profitability drag from bed expansion cycle is already embedded, with new capacity ramping up at a healthy pace, the note added.
Key risks
Macquarie listed the following key risks for the two stocks:
- Supreme Court extending margin cap beyond oncology drugs.
- Higher-than-expected profitability drag from new hospitals.
- For Apollo Hospitals, elevated 24/7 costs limited HealthCo margin expansion.
How Did Apollo Hospitals Fare In Q2?
Apollo Hospitals reported its second quarter results earlier this month. Its net profit rose 33.6% to ₹660 crore from the previous year. Its revenue increased by 23% to ₹7,615 crore from ₹6,189 crore in the previous fiscal. Both were above Street estimates of ₹632 crore and ₹7,515 crore, respectively.
The company’s EBITDA increased 28.8% to ₹1,191 crore from ₹925 crore last year. It was also in-line with Street estimates of ₹1,160 crore.
Its EBITDA margin expanded to 15.6% from 14.9% in the year-ago period also beating Street expectations of 15.4%.
The company’s hospital occupancy improved to 73% from 69% last year. Its inpatient volumes were up 14%, while the average revenue per occupied bed increased 8% from last year to ₹1,86,880.
Stock reaction
Of the 33 analysts who have coverage on the stock, 29 have a “buy” rating and four have “hold” ratings on the stock.
Shares of Apollo Hospitals gained 5.3% to hit an intraday and fresh record high of ₹9,205 apiece on Friday. The stock is now trading 4.6% higher at ₹9,138. With this, the stock has extended its 2026 advance to 28.5%.
Apollo Hospitals shares hit record high after Macquarie double upgrade, projects 20% upside
